MAI Capital Management Acquires 28,164 Shares of Trevi Therapeutics, Inc. $TRVI

MAI Capital Management lifted its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 2.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,385,050 shares of the company’s stock after purchasing an additional 28,164 shares during the period. MAI Capital Management’s holdings in Trevi Therapeutics were worth $8,712,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new position in Trevi Therapeutics during the fourth quarter valued at about $49,000. Squarepoint Ops LLC acquired a new position in shares of Trevi Therapeutics during the 4th quarter valued at about $58,000. Two Sigma Advisers LP acquired a new position in shares of Trevi Therapeutics during the 4th quarter valued at about $66,000. Cantor Fitzgerald L. P. bought a new position in shares of Trevi Therapeutics in the 4th quarter valued at approximately $82,000. Finally, ProShare Advisors LLC lifted its holdings in Trevi Therapeutics by 86.4% in the 4th quarter. ProShare Advisors LLC now owns 20,685 shares of the company’s stock worth $85,000 after purchasing an additional 9,589 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Price Performance

Shares of Trevi Therapeutics stock opened at $7.26 on Monday. The company has a market cap of $884.10 million, a PE ratio of -17.29 and a beta of 0.71. The firm has a fifty day moving average price of $6.92 and a two-hundred day moving average price of $6.30. Trevi Therapeutics, Inc. has a fifty-two week low of $2.36 and a fifty-two week high of $8.78.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. Analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TRVI has been the topic of several analyst reports. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, June 2nd. HC Wainwright assumed coverage on shares of Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a “buy” rating and a $21.00 target price on the stock. Morgan Stanley initiated coverage on shares of Trevi Therapeutics in a research report on Thursday, August 21st. They set an “overweight” rating and a $18.00 target price for the company. Wall Street Zen downgraded Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, June 6th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Two equities research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.11.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.